CSL (FRA:CSJA) Research & Development: €1,053 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CSJA CSL Ltd FRA:CSJA
62 GF Score
Price €24.40
GF Value €38.74
! 6 Warning Signs
View Full Analysis

What is CSL Research & Development?

CSL FRA:CSJA +2.52% 62 Research & Development is €1,053 Mil as of Jun. 2026. GuruFocus rates FRA:CSJA with a GF Score™ of 62/100 and a GF Value™ of €38.74. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. CSL's Research & Development for the six months ended in Jun. 2026 was €541 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was €1,053 Mil.

CSL  (FRA:CSJA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CSL Research & Development Related Terms

CSL Research & Development Historical Data

* Premium members only.

The historical data trend for CSL's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSL Research & Development Chart

CSL Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,093.77 1,139.91 1,328.47 1,178.25 1,061.56

CSL Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Jun25 Dec25 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 614.39 706.04 0.00 512.40 540.76
FRA:CSJA
62GF Score
CSL Ltd FRA:CSJA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSL Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1,053 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €1,053 Mil mean?
CSL (FRA:CSJA) has a Research & Development of €1,053 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on CSL and its competitors.
Is CSL's Research & Development too high?
CSL's current Research & Development is €1,053 Mil. Overall, CSL has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does CSL's Research & Development compare to VRTX and REGN?
CSL's Research & Development of €1,053 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on CSL and its competitors. CSL's current Research & Development is €1,053 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
CSL (FRA:CSJA) has a current Research & Development of €1,053 Mil. The stock's GF Value™ is €38.74, compared to a current price of €24.40 — trading 37% below its estimated fair value. The current Research & Development is €1,053 Mil. CSL's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For CSL (FRA:CSJA), the current Research & Development is €1,053 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSL (FRA:CSJA) Overvalued in 2026?

Based on GuruFocus' analysis, CSL stock appears to be undervalued. The current stock price of €24.40 is trading 37% below its estimated GF Value™ of €38.74.

Key valuation signals for FRA:CSJA:

  • Research & Development: €1,053 Mil
  • GF Value™: €38.74 vs. price of €24.40 (37% below fair value)
  • GF Score™: 62/100 with 6 warning signs

No single metric tells the full story. See the FRA:CSJA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSL Business Description

Address 655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
62GF Score

Get the complete analysis for FRA:CSJA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€24.40
Price
€38.74
GF Value